Please login to the form below

Not currently logged in


This page shows the latest CXA-201 news and features for those working in and with pharma, biotech and healthcare.

Cubist publishes positive data on novel antibiotic

Cubist publishes positive data on novel antibiotic

combination CXA-201 (ceftolozane/tazobactam) for complicated urinary tract and intra-abdominal infections in the US in April. ... CXA-201 is also due to be filed in Europe later this year and is in phase III testing for hospital-acquired bacterial

Latest news

  • Cubist posts positive phase III antibiotic data Cubist posts positive phase III antibiotic data

    CXA-201 combines a novel cephalosporin (ceftolozane) with a well-established beta-lactamase inhibitor and is designed to tackle Gram-negative bacterial infections. ... Data from the latest study demonstrated that CXA-201 was within 10 per cent of

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Atlantis Healthcare

Atlantis Healthcare is a global leader in optimising patient self-management. Established in 1996, we design, develop and implement scalable solutions...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...